Compare Packaging Corporation of America (PKG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Packaging Corporation of America vs Sanofi SA — how do they compare? Packaging Corporation of America trades at $231.22 (market cap $20.25B), while Sanofi SA trades at $40.1 (market cap $96.81B). The key difference: Sanofi SA is far larger — about 4.8× Packaging Corporation of America's market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Packaging Corporation of America for 45 Days and Sanofi SA for 94 Days on average.
| PKG | SNY | |
|---|---|---|
Market Cap | $20.25B | $96.81B |
Volume | 491,102 | 2,081,815 |
Sector | Consumer Cyclical | Health |
52-Week High | $257.43 | $52.34 |
52-Week Low | $191.68 | $39.51 |
Typical Hold Time | 45 Days | 94 Days |
Enterprise Value | $24.06B | $116.20B |
Dividend Yield | 2.64% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Packaging Corporation of America (PKG) trades at $227.25, down 1.08% with bearish technical signals despite recent earnings beats. The company maintains solid fundamentals with $9.5B revenue projection for 2026 and 7.25% net margin, though facing margin compression from cost pressures. Recent institutional buying by BlackRock and Bank of New York Mellon contrasts with mixed analyst ratings.
PKG offers steady packaging demand exposure but faces headwinds from rising input costs and competitive pressures. The 19.8% upside to consensus price target of $272.43 presents opportunity, though investors should monitor Q3 2026 earnings results on October 22 for margin trajectory confirmation amid bearish technical indicators.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
